Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 32 of 47 January/February 2017 Clinical OMICs 31 ActX and CompuGroup Partner to Bring Genomic Data to Electronic Health Records Seattle-based genomic decision support company ActX and healthcare software solutions provider CompuGroup Medical (CGM) US have announced a partner- ship to bolster the value of electronic health records (EHRs) to provide actionable information for precision medicine. ActX employs a saliva test to collect patients' genetic information. The com- pany then takes the collected data and integrates it with CGM's EHR products CGM webEHR and CGM CLINICAL. The seamless integration promises to give healthcare providers the information they need to provide real-time genomic decision support directly through a patient's EHR. With this new partnership, physicians using CGM's systems will be able to automatically screen a patient's profile for drug efficacy, adverse reactions and dosing when prescribing a new drug. They will also have access to patients' full genomic profiles to monitor non-medication related risks, such as a genetic pre- disposition for cancer. "We think that the only way to make genetics truly practical for physicians is to embed a genomic decision support directly into the electronic health record," says Andrew Ury, founder and CEO of ActX. " Physicians are busy and not [all] of them are experts on genetics, and really no one can hold all the genetic infor- mation in their hand, [which is why] we need computerized decision support." According to Ury, most genetic information is currently deliv- ered via pdfs, which works for a few medications or a couple of genes but does not scale well. This, Ury emphasizes, is why integrating genetic data into the electronic health record itself is so important. ActX has additional partnerships with a number of other EHR providers, including Allscripts, and Cerner, as well as ePrescribing solution NewCrop. The company plans to continue building partnerships with other EHR companies in the years to come. "Our goal is to help improve patient care, help reduce health care costs, and improve quality by tailoring therapy to the individual patient," says Ury. "I think this is the best way to accomplish it."—Diana Kwon EMD Serono, MD Anderson Oncology Collaborate to Leverage APOLLO Data and Research Platform EMD Serono (the healthcare business of Merck) and The University of Texas MD Anderson Cancer Center have embarked on a three-year strategic collaboration with the aim of more quickly advancing the development of investigational can- cer therapies in four cancers: breast, col- orectal, glioblastoma, and leukemia. EMD Serono will be the first com- pany to gain access to the Adaptive Patient-Oriented Longitudinal Learning and Optimization Platform (APOLLO). A research platform developed by MD Anderson, APOLLO standardizes the long-term collection of patients' medical history and data derived from tissue sam- ples in order to better understand the biology of cancer to promote research- driven patient care. The collaboration w i l l e n c o m p a s s both biomarker-fo- cused preclinical research and clin- ical trials in spe - cific tumor types, aimed at identi- fying biomarkers of response, and resistance. " This collabora- tion illustrates our c o m m i t m e n t t o delivering mean- ing ful value to patients by rapidly progressing our immuno-oncology pipe- line, focusing on the identification of innovative biomarkers, together with our partner, the prestigious MD Anderson Cancer Center," says Belén Garijo, CEO, healthcare, and member of the executive board of Merck. (continued on next page) akindo / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017